Randomized, 8‐week, double‐blind, placebo‐controlled trial of vortioxetine in Japanese adults with major depressive disorder, followed by a 52‐week open‐label extension trial

By  

PSYCHIATRY AND CLINICAL NEUROSCIENCES, Vol. 72, Iss. 2, 2018-02 ,pp. : 103-115

John Wiley & Sons Inc

Access to resources Recommend Favorite

A randomized, double-blind trial of 2.5 mg and 5 mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder

By Mahableshwarkar Atul R.   Jacobsen Paula L.   Chen Yinzhong  

Current Medical Research and Opinion, Vol. 29, Iss. 3, 2013-03 ,pp. : 217-226

Informa Healthcare

Access to resources Recommend Favorite

A randomized, double-blind, 24-week study of escitalopram (10 mg/day) versus citalopram (20 mg/day) in primary care patients with major depressive disorder

By Colonna Lucien   Andersen Henning Friis   Reines Elin Heldbo  

Current Medical Research and Opinion, Vol. 21, Iss. 10, 2005-10 ,pp. : 1659-1668

Informa Healthcare

Access to resources Recommend Favorite

A randomized, double‐blind, placebo‐controlled trial to evaluate the efficacy, safety, and tolerability of long‐term treatment with prucalopride

By  

NEUROGASTROENTEROLOGY & MOTILITY (ELECTRONIC), Vol. 27, Iss. 6, 2015-06 ,pp. : 805-815

John Wiley & Sons Inc

Access to resources Recommend Favorite

Efficacy and safety of dapagliflozin monotherapy in people with Type 2 diabetes: a randomized double‐blind placebo‐controlled 102‐week trial

By  

DIABETIC MEDICINE, Vol. 32, Iss. 4, 2015-04 ,pp. : 531-541

John Wiley & Sons Inc

Access to resources Recommend Favorite